Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term Nonprogressors
between a variety of host and viral factors are known to affect HIV-1 pathogenesis and could influence disease progression. These factors include host susceptibility, viral tropism, genetic variability and cytopathicity, cellular and humoral immunity, and concomitant infections [11] .
No demographic characteristics unique to LTNPs have been identified; however, recent studies have demonstrated that LTNPs have normal lymph node architecture, less virus' 'trapping" in the follicular dendritic cell network of germinal centers [12] , and persistent, albeit low, levels of virus in their plasma, peripheral blood mononuclear cells (PBMC) [12, 13] , and lymph node mononuclear cells [12] . The inability to culture virus from plasma from LTNPs [12, 13] and the difficulty in isolating virus from the PBMC ofLTNPs [2, 4, [12] [13] [14] suggest that viral replication is contained in LTNPs to a greater extent than in most progressors. Current information suggests that virus containment in LTNPs might be the result of infection with defective viruses in some persons [13, 15] and the presence of robust cellular and humoral immune responses in others [12] [13] [14] . Virologic and immunologic characteristics ofLTNPs vary [4, 7, [12] [13] [14] [15] , suggesting that LTNPs comprise a diverse group of persons, some of whom might, with time, be expected to progress sooner than others, while other LTNPs may never progress.
A better understanding of long-term nonprogression of HIV-1 infection could come from the study of neutralizing and infection-enhancing antibodies. Neutralizing antibodies are considered important to the control of viral replication [1] , whereas infection-enhancing antibodies have been associated with enhanced viremias, rapid disease progression, increased disease severity, and vaccine failures in other virus systems [16, 17] . The identification of infection-enhancing antibodies in sera from most HIV-1-infected persons [18] [19] [20] [21] and from many gpl60-vaccinated volunteers [22, 23] has raised concerns about HIV-I vaccine safety and efficacy [24] [25] [26] . Study of LTNPs could add to our understanding of neutralizing antibodies and address concerns over infection-enhancing antibodies.
Methods
Cells and laboratory strains ofvirus. The human lymphoblastoid cell line H9 and HIV-I strains II1 B and MN were obtained from Robert Gallo (National Cancer Institute, NIH). Stocks of the 2 strains were derived from cell-free culture fluids of chronically infected H9 cells as described previously [27] . A separate stock of HlV-I mB was prepared in phytohemagglutinin (PHA)-stimulated PBMC in a similar fashion. HTLV-1-transformed MT-2 cells were obtained from Douglas Richman (University of California, San Diego VA Medical Center). These cells express a high density of complement receptor type 2 (CR2/CD21), which makes them highly sensitive to the detection of complement-mediated, antibody-dependent enhancement (C'-ADE) of HIV-I infection [28] . PBMC in leukopacs (Durham Regional American Red Cross) prepared from multiple HIV-L-negative donors were isolated by centrifugation through lymphocyte separation medium (Organon-Teknika/Akzo, Durham) and incubated at 2 X 10 6 cells/mL in stimulation medium (RPMI 1640 containing glutamine, 20% heatinactivated fetal bovine serum, 50 ILg of gentamicin/mL, 3 ILg of PHA-P/mL, and 4% purified human interleukin [IL]-2) for 2 days. The PBMC were then washed and resuspended in growth medium containing IL-2 before being used for virus isolation, neutralization assays, and preparation of a stock of HlV-I IIIB.
HIV-l-infected subjects. LTNPs were defined as having documented HIV-I infection for > 7 years, CD4 cell counts of > 600 cells/rum", and no symptoms related to HIV-I infection. With the exception of patients 17 and 24, no patients had ever received antiretroviral therapy. Of the 19 LTNPs included in this study, 17 had been infected for~10 years (table I) . One exception to this definition was patient 18, who was infected for 14 years but had a CD4 cell count of 451 cells/mnr'. Additional information on II of the LTNPs included in this study (i.e., patients 1-10 and 13) is presented in a previous report [12] . LTNPs were enrolled in either the Multicenter AIDS Cohort Study, the San Francisco City Clinic Cohort Study, or the National Institute of Allergy and Infectious Diseases lymph node study. All LTNPs had normal CD8 cell counts and were culture-negative for infectious virus in their plasma. HIV-I-infected, non-LTNP subjects were selected from patients attending the AIDS Clinic at Duke University Medical Center. Non-LTNPs from whom virus isolates were obtained are described along with information on their viruses in table 2. Virus isolation attempts were not made on the remaining non-LTNPs, who included 3 symptomatic patients with <50 CD4 cells/mm" (patients M35064, R16458, and W44991) and asymptomatic patients who had been infected for <7 years and had~600 CD4 cells/nun'. On the basis of current estimates, most of these asymptomatic patients would be expected to progress to AIDS before meeting the criteria for LTNPs [3, [8] [9] [10] .
Isolation of HIV-I from PEMC and lymph nodes. Primary isolates were obtained by standard PBMC coculture. In brief, 2 X 10 6 PBMC or lymph node mononuclear cells were incubated with PHA-stimulated, allogeneic PBMC in growth medium containing IL-2. Culture fluids were collected every 2 days, clarified of cells by low-speed centrifugation and 0.45-ILm filtration, and stored in aliquots at -70°C until use. Virus yields were quantified by p24 immunoassay (Organon-Teknika/Akzo). Maximum virus yields for all isolates were obtained within 6-10 days of coculture. Culture fluids obtained at the peak of virus production were used for all subsequent evaluations without further passage. Syncytiuminducing (SI) and non-syncytium-inducing (NSI) virus phenotypes were determined in PBMC and MT-2 cells by monitoring of syncytium formation and p24 production over 21 days. There was complete agreement in phenotype between both cell types. NSI variants were unable to infect MT-2 cells, as determined by the absence of p24 production at various time points throughout the 21-day incubation period. MT-2 tropism is a strong correlate of SI and NSI phenotypes in PBMC and has been used extensively to study associations of SI and NSI variants in HIV-I pathogenesis [29, 30] . Patient characteristics, virus phenotype, and maximum virus yields during PBMC cocuIture are summarized in tables I and 2.
Virus neutralization. Neutralization of H9-grown HIV-I strains II1 B and MN was measured in an MT-2 cell-killing assay done in 96-well plates as previously described [27] . In brief, cellfree virus and serial dilutions of test sera were incubated in triplicate at 37°C for 30 min before the addition of MT-2 cells (5 X 10 4/well). Virus concentrations were 3 X 10 4 TCID so , containing 12.5 ng p24/well for strain II1 B , and I X 10 3 TCID so , containing NOTE. SI, syncytium-inducing; NSI, non-SI; PCP, Pneurnocystis carinii pneumonia; 01, opportunistic infections.
-Maximum during isolation (ng p24/mL).
4.8 pg p24/well for strain MN. Infection led to extensive syncytium formation and virus-induced cell killing in 3-4 days in the absence of neutralization, while little or no syncytia and cell killing were observed in the presence of neutralization. Neutralization was quantified by staining viable cells with neutral red: Uptake, quantified at a wavelength of 540 nm, was linear from an absorbance of 0.25 to 0.85, corresponding to 2 X 10 4 to 25 X 10 4 viable cells/ well [27] . Percent protection was calculated by the difference in absorption (A S40 ) between test wells (cells, serum sample, and virus) and virus control wells (cells and virus) divided by the difference in absorption between cell control wells (cells only) and virus control wells. Assays were harvested when cytopathic effect in virus control wells was >70% but <100%. Neutralizing titers were defined as the reciprocal of the serum dilution required to protect at least 50% of the cells from virus-induced killing. Neutralization of primary isolates was measured in PHA-stimulated PBMC using p24 immunoassay to quantify infection. Cellfree virus and test sera (1:16 dilution) were incubated at 37°C for 30 min in duplicate wells of a 96-well U-bottom plate before adding PHA-stimulated, allogeneic PBMC. Plates were incubated an additional 3 h, and the cells were washed three times with 200 J.1L of growth medium to remove virus inoculum and test serum. Washed cells were suspended in 250 J.1L of IL-2 growth medium and incubated in fresh 96-well plates. Virus production was quantified by p24 immunoassay on cell suspensions (25 J.1L) collected daily beginning on day 2. Neutralization was measured just before virus production in the absence of test sera (control) had peaked. Samples with ;;.80% reduction in p24 synthesis were considered positive.
Infection-enhancing antibodies. C'-ADE of HIV-1IIIB infection in MT-2 cells was measured in 96-well plates using fresh, normal human serum (Sigma, St. Louis) as a source of complement as described [19, 23] with some modification. In brief, serial 3-fold dilutions of heat-inactivated test sera were made in duplicate in 100 J.1L of growth medium containing a 1:27 dilution of fresh normal human serum. Cell-free virus (50 J.1L containing 3 X 10 3 TCID so and 1.3 ng p24) were added and incubated at 37°C for 30 min before MT-2 cells (5 X 104/ cells well) were added. Plates were incubated an additional 3 h before cells were washed three times with 200 J.1L of growth medium to remove virus inoculum and test serum. Washed cells were suspended in 250 J.1L of fresh growth medium without normal human serum and incubated in 96-well plates.
Infection was quantified by p24 immunoassay (Organon-Teknika/Akzo) 2 days later. On the basis of results obtained with a panel of control sera from HIV-1-negative persons, an increase in p24 production >2.5-fold greater than background (no test serum added to virus) was considered positive for infection enhancement. C' -ADE activity was defined as the reciprocal of the last serum dilution to show enhancement (titer), the reciprocal serum dilution producing the greatest enhancement (peak), and the magnitude of enhancement at the peak dilution (power), represented as the fold increase in p24 production over background.
C'-ADE of PBMC-grown primary isolates was done in MT-2 as described above, except that a single serum dilution (1:30) was evaluated, and fresh normal human serum was added at a 1:3 dilution as a source of complement. Values showing ;;.2-fold increased p24 production were considered positive.
Statistical analyses. Statistical analyses were done using StatView software (Abacus Concepts, Berkeley, CA). The significance of neutralizing antibody titers to HIV-1 strains III B and MN and the power of C' -ADE activity were compared by use of Student's t test (two-tailed, unpaired analysis). For the statistical analysis of C' -ADE, half the cutoff value of 2.5 (i.e., 1.25) was used for samples with no detectable activity. Neutralization frequency with primary isolates was analyzed by use of Fisher's exact test. P <.05 was considered significant.
Results

Primary isolates from LTNPs and non-LTNPs.
Primary HIV-1 isolates were obtained from PBMC and lymph node mononuclear cells from all 3 LTNPs for whom isolation attempts were made (table 1). Each isolate had an NSI phenotype and a maximum virus yield ranging from 37 to 650 ng p24/ mL during PBMC coculture. Additional primary isolates were obtained from PBMC from 9 HIV-1-infected persons who were non-LTNPs. Their maximum virus yields ranged from 10 NOTE. NT, not tested due to limited supply of sample.
* Defined as reciprocal of last serum dilution to show enhancement (titer), reciprocal serum dilution producing greatest enhancement (peak), and magnitude of enhancement at peak dilution (power), represented as the fold increase in p24 production over background.
to 200 ng p24/mL and included 5 isolates with an SI phenotype and 4 with an NSI phenotype (table 2) . Of note, I isolate with an NSI phenotype was obtained from a progressor (patient H78639) just 2 weeks before the patient died from an AIDSrelated illness. Neutralizing antibodies. Neutralizing antibodies to 2 related but genetically diverse clade B laboratory strains of HIV-I (i.e., IlI B and MN) were evaluated in the MT-2 cellkilling assay using sera from 12 LTNPs and 13 non-LTNPs who were asymptomatic and infected for <7 years (table  3) . Average titers of neutralizing antibodies to both viruses were higher for sera from LTNPs, but this difference was statistically significant with MN only (IlI B , P = .087; MN, P = .020).
Using viruses grown and assayed in PBMC, we further evaluated neutralizing antibodies with HIV-I IIIB and primary isolates from 8 non-LTNPs (table 4) . Sera from both groups neutralized HIV-I I1IB at a high and approximately equal frequency (75% for LTNPs; 67% for non-LTNPs). In contrast, the frequency of neutralizing primary isolates was relatively low for sera from both groups: 14.9% for LTNPs vs. 1.3% for nonLTNPs (P = .002). Experiments with primary isolates from 3 LTNPs revealed no significant difference in the frequency of neutralization between sera from LTNPs (21.4%) and nonLTNPs (11.6%; P = .226) (table 5). While each virus from LTNPs was sensitive to neutralization by sera from at least 2 LTNPs, none were sensitive to neutralization by autologous serum obtained at the time of virus isolation. Of interest, paired viruses from lymph nodes and PBMC ofLTNPs showed similar patterns of neutralization by heterologous sera. Last, viruses from LTNPs and non-LTNPs showed little difference in their sensitivity to neutralization by heterologous sera (P = .046).
C-ADE antibodies. C'-ADE activity to HIV-I IIIB was detected in sera from 5 of 12 LTNPs and 6 of 9 non-LTNPs (table 3). Sera from 3 and 2 LTNPs had higher titer and peak values, respectively, than any observed with sera from nonLTNPs, but these higher values differed by only I or 2 dilutions from the highest values for non-LTNPs. No significant difference in the power of enhancement was observed between the 2 groups (P = .369).
Additional C' -ADE evaluations were made using 5 primary isolates with an SI phenotype (table 6). NSI variants could not be evaluated in C' -ADE assays because of their inability to infect the indicator MT-2 cells. Therefore, all primary isolates used in C'-ADE assays were obtained from progressors. Each isolate was susceptible to C' -ADE activity by sera from both groups: enhancement was seen in 12 (54.5%) of 22 tests with sera from LTNPs and 18 (47.4%) of 38 tests with sera from non-LTNPs (table 6). Power of enhancement was sometimes considerably greater than the maximum 3.9-fold increase in p24 production observed with HIV-1IIlB. Of the virus-serum combinations for which neutralization data were available (see * and t, table 6), 20 (11 LTNPs, 9 non-LTNPs) had C'-ADE in MT-2 cells and no neutralization in PBMC. Three more combinations (all LTNPs) produced neutralization without C'-ADE activity, and 13 combinations (7 LTNPs, 6 non-LTNPs) had no C' -ADE or neutralization. These different patterns did not reflect unique immune properties of the isolates since all exhibited different sensitivity to C' -ADE and neutralization by some sera (tables 4 and 6).
Discussion
The study of LTNPs affords unique opportunities to identify viral and host factors that may be responsible for delaying or preventing disease progression in HIV-1-infected persons. A distinguishing feature of sera from LTNPs studied here was their higher average titer of neutralizing antibodies to HIV-I NOTE. NT, not tested due to limited supply of sample.
Montefiori et al. JID 1996; 173 (January) strains IlIa and MN compared with nonprogressors who did not meet the criteria for being classified as LTNPs because they were infected <7 years. On the basis of current estimates [2] [3] [4] [5] [6] [7] , no more than 1 of these non-LTNPs may be expected to become a LTNP, which should have little impact on the outcome of our comparison. The vigorous neutralizing responses to 2 genetically diverse, clade B isolates is evidence that LTNPs are constantly exposed to viral antigens, particularly the envelope glycoproteins [31] . The low levels of HIV-1 seen in the peripheral blood samples and lymph nodes of many of these LTNPs [12] indicates that constant exposure to low-level virus is sufficient to drive strong antibody responses in immunocompetent persons.
The potential benefit of antibodies that neutralize laboratory strains of HIV-1 remains uncertain since their presence does not predict the ability to neutralize primary isolates in vitro [32, 33] . In fact, most primary isolates of HIV-1 are difficult to neutralize by antibodies from infected or vaccinated persons [32] [33] [34] , which could be a contributing factor to the failure of the immune response to prevent disease progression [35] [36] [37] .
Neutralizing antibodies in sera from LTNPs were recently reported to be broader-reactingthan those from non-LTNPs when tested against primary isolates [13] . Our results agree that sera from LTNPs have broader neutralizing activity when tested against primary isolates. The broadness of the response could be due to genetic variation in LTNP viruses or to multiple exposures to HIV-1 variants from other infected persons. The frequency at which this neutralization occurred (14.9%), however, was much lower than the 78% reportedpreviously [13] . Differences in assay conditions do not appear to explain this discrepancy since both studies used viruses from non-LTNPs and similar procedures in PBMC. An alternative explanation is that LTNPs include different subgroups of patients distinguished by the quality of their neutralizing antibodies. Virus load would appear to be another differentiating factor, since average levels of viral RNA and DNA in peripheral blood were higher in the LTNPs studied here [12] than in those described by Cao et al. [13] .
Considering these observations, virologic and immunologic profiles may be used to define at least 2 subgroups of LTNPs: those having a moderately improved quality of neutralizing antibodies and~lO-fold lower levels of viral RNA and DNA in their peripheral blood relative to progressors [12] and those having high-quality neutralizing antibodies and > 1O-foldlower levels of viral RNA and DNA relative to progressors [13] . Additional subgroups of LTNPs are likely to be identified as new data accumulate, and it will be important to determine whether certain subgroups will progress sooner than others after long-term follow-up. NOTE. PBMC, peripheral blood mononuclear cells; NT, not tested due to limited supply ofsample. H78639  NT  NT  NT  W25798  P59423  NT  NT  V89872  M35064 + Studies similar to those described above but with viruses from LTNPs have been hampered by the difficulty in isolating HIV-l from patients [13] . Perhaps this difficulty is due to low levels of viral replication or to the presence of defective viruses. Our success in isolating HIV-1 from PBMC and lymph nodes of 3 LTNPs is further evidence that at least some LTNPs harbor replication-competent viruses. The fact that all 6 HIV-1 variants from LTNPs had an NSI phenotype is consistent with previous reports that NSI variants are mostly associated with asymptomatic infection [29, 30, 37] and suggests that the absence of SI variants contributes to long-term nonprogression of HIV-I. The strikingly similar neutralizing phenotype of paired viruses from PBMC and lymph nodes of 2 LTNPs (patients 22 and 24) is evidence that viruses isolated from these two anatomic sites share common neutralizing determinants.
Our observation that viruses from LTNPs were neutralized infrequently by heterologous sera and not at all by autologous sera suggests that HIV-1 in LTNPs is exposed to immune selection mechanisms similar to those that give rise to neutralization-escape variants in progressors [35~37] . Autologous neutralizationwas observed with only 1 of 3 previously evaluated LTNPs [13] , adding further support to the conclusion that viruses from LTNPs are generally resistant to neutralizationby • Sera that neutralized peripheral blood mononuclear cell (PBMC)-grown virus inPBMC assay.
t Sera that did not neutralize PBMC-grown virus inPBMC assay.
autologous antibodies. Additional evidence that neutralizationescape variants arise over time in LTNPs will require studies of sequential sera and virus isolates. Important information concerning the clinical relevance of serum antibody responses in HIV-1 infection could come from the study of infection-enhancing antibodies in LTNPs. There are a number of concerns regarding whether these antibodies contribute to HIV-1 pathogenesis by facilitating virus entry or expanding the tropism of the virus [16-21, 38, 39] . It has also been suggested that follicular dendritic cells may transmit infectious virus to circulating CD4 cells, with the transmitted virus residing on the surface of the follicular dendritic cells by a process involving complement and complement receptors associated with C'-ADE [40] [41] [42] . Sera from LTNPs might be expected to lack infection-enhancingactivity, but in the current study, the sera demonstrated C' -ADE activity against HIV-l m B and primary isolates at about the same frequency seen in sera from non-LTNPs (table 6 ). This outcome agrees with our previous observation that C'-ADE does not correlate with stage of disease or predict disease progression [19] .
Many of the virus-serum combinations that were positive for C' -ADE were negative for neutralization in PBMC (table  4) , providing further evidence that C'-ADE in the absence of neutralization does not predict disease progression. Perhaps LTNP 24 LTNP 22 LTNP 18 cell-mediated immunity or other antibody mechanisms can effectively override C' -ADE in vivo. In addition, complementactivating antibodies might facilitate the clearance of HIV-1 immune complexes through the mononuclear phagocyte system as a possible protective mechanism [41, 43] . Unfortunately, autologous C' -ADE activity could not be evaluated since the HIV-l variants isolated from LTNPs could not infect MT-2 cells. Additional studies are needed when assays to detect C'-ADE with NSI variants become available.
The observation that long-term nonprogression of HIV-1 infection is not associated with the presence of autologous neutralizing antibodies or the absence of C' -ADE indicates that other viral or host factors may be more important. Included among these factors are one or more determinants of the NSI phenotype, virus tropism, virus replication capacity, such as deletions in the nef gene [15] , the presence of robust cellmediated immune responses [12] [13] [14] , or other antibody activities [41] [42] [43] . No single determinant of long-term nonprogressing HIV-1 infection will likely be common to all LTNPs, and their virologic and immunologic profiles may be useful in defining different subgroups for further study.
